ALA flies on a " vector anns " for a trial about 18-24 months away.
CHM already got its one for a trial commenecing soon, why aren't we flying too?
09 March 2023
“Vector supply continues to significantly challenge the cell therapy industry with current
backlogs of more than a year to access vector manufacturing,” said Chimeric CEO and Managing
Director Jennifer Chow. “Securing vector supply for the CHM 2101 Phase 1A clinical trial marks
a significant milestone for advancing CHM 2101 towards the clinic and patients that need novel
therapies to treat advanced gastrointestinal and neuroendocrine tumours.”
GLTA
ALA flies on a " vector anns " for a trial about 18-24 months...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |